Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $39.25.

Several equities research analysts have weighed in on GMAB shares. Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Truist Financial reaffirmed a “buy” rating and set a $48.00 price target (down from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Wall Street Zen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Finally, HC Wainwright lowered their price target on shares of Genmab A/S from $41.00 to $39.00 and set a “buy” rating on the stock in a report on Tuesday.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Osaic Holdings Inc. grew its holdings in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares in the last quarter. CWM LLC grew its stake in shares of Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after buying an additional 603 shares in the last quarter. NewEdge Advisors LLC increased its stake in Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares during the period. Brown Brothers Harriman & Co. boosted its position in Genmab A/S by 143.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after buying an additional 780 shares during the period. Finally, Founders Capital Management grew its stake in Genmab A/S by 40.0% during the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Trading Up 2.4%

NASDAQ GMAB opened at $33.88 on Friday. The stock has a market cap of $21.76 billion, a PE ratio of 14.42, a P/E/G ratio of 18.64 and a beta of 0.90. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $35.43. The stock’s 50 day moving average is $32.17 and its 200 day moving average is $28.64.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million. On average, analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.